-
Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a cooperation intention agreement with the United Arab Emirates’ Gulf Medical University. The collaboration aims to encompass talent exchange, channel construction, scientific research, and commercial translational research, among other areas. Financial details of the agreement have…
-
FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia
•
Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval from the US Food and Drug Administration (FDA) for the treatment of patients aged 12 and above with transfusion-dependent β-Thalassemia (TDT). This marks a significant milestone as Casgevy becomes the world’s first CRISPR-based gene editing…
-
Sun Yat-sen University Researchers Develop AI Model for Early Ovarian Cancer Detection
•
Researchers at Guangzhou’s Sun Yat-sen University Cancer Center have made a significant breakthrough with the development of an artificial intelligence (AI)-based model designed for the early detection of ovarian cancer. This cost-effective AI model aims to assist in diagnosing the deadliest form of gynecological cancer worldwide. In China, early-stage diagnosis…
-
Shanghai-Based NK CellTech Earns FDA IND Clearance for Non-Genetically Modified NK Cell Therapy
•
NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for its proprietary non-genetically modified natural killer cell therapy, NK010, for the treatment of ovarian cancer. This milestone marks NK CellTech as…
-
Hainan Province Unveils Measures to Support Innovative Drugs and Medical Devices Development
•
Hainan provincial bureaus, including the Healthcare Security Administration (HSA), Healthcare Commission, and Medical Products Administration, along with five other bureaus, have jointly issued a set of Measures to “Support the Development of Innovative Drugs and Medical Devices in Hainan Province.” The initiative aims to ensure seamless integration between the market…
-
Shanghai Medical Products Administration Issues Trial Measures for Pharmaceutical Quality and Safety Personnel
•
The Shanghai medical products administration has released the “Measures for the Management of Key Quality and Safety Management Personnel of Drug Production and Operation Enterprises in Shanghai (Trial)”. These measures aim to tackle current issues in managing key personnel responsible for drug quality and safety within enterprises and to bolster…
-
USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo
•
In a surprising turn of events in the ongoing intellectual property dispute, the US Patent and Trademark Office (PTO) has invalidated a 2020 patent for conjugation compounds used in antibody-drug conjugates (ADCs), which was held by Pfizer’s (NYSE: PFE) subsidiary Seagen and contested by Japan’s Daiichi Sankyo (TYO: 4568). The…
-
Bayer Unveils New Operating Model to Drive Profitable Growth Amid Challenges
•
Facing a challenging business landscape, Germany’s Bayer (ETR: BAYN) has announced a new operating model aimed at enhancing its performance and returning to profitable growth. The plan includes significant job cuts as part of an ongoing staff reduction program, with compulsory redundancies set to begin in 2027. In contrast to…
